Scherle Peggy 4
4 · Prelude Therapeutics Inc · Filed Aug 17, 2021
Insider Transaction Report
Form 4
Scherle Peggy
Chief Scientific Officer
Transactions
- Sale
Common Stock
2021-08-13$35.07/sh−2,286$80,161→ 172,920 total - Exercise/Conversion
Common Stock
2021-08-13$1.43/sh+1,728$2,471→ 175,206 total - Exercise/Conversion
Common Stock
2021-08-13$1.89/sh+558$1,055→ 173,478 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-08-13−558→ 42,672 totalExercise: $1.89Exp: 2030-03-26→ Common Stock (558 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-08-13−1,728→ 34,732 totalExercise: $1.43Exp: 2028-11-12→ Common Stock (1,728 underlying)
Footnotes (5)
- [F1]Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
- [F2]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F4]The stock option vested as to 25% of the total shares monthly beginning on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
- [F5]The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.